as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹335.0
Change
-0.05 (-0.01%)
Open
₹337.0
Prev. Close
₹335.05
Day High
₹342.0
Day Low
₹330.2
Volume Analysis
Traded
251,356
Delivered
105,831
Delivery %
42.1%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (-81.5%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (35/100)
- •Low operating margin (-4152.0%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹353.06 | ₹347.53 | ₹341.26 | ₹335.73 | ₹329.46 | ₹323.93 | ₹317.66 |
| Fibonacci | ₹347.53 | ₹343.02 | ₹340.24 | ₹335.73 | ₹331.22 | ₹328.44 | ₹323.93 |
| Camarilla | ₹338.25 | ₹337.16 | ₹336.08 | ₹335.73 | ₹333.92 | ₹332.84 | ₹331.76 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+103.41%
1 Week
-0.86%
1 Month
-8.21%
3 Months
+19.37%
6 Months
+127.23%
1 Year
+60.25%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-41.46%
Net margin -3911.11% × asset turnover 0.01x × equity multiplier 1.06x
Company Overview
Sector
Healthcare
Market Cap
₹9,466 Cr
ROE
-81.5%
Book Value
₹22.4
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Suven Life Sciences Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 35/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-81.5%); promoter holding is falling.
TopFund Score — Fundamentals Quality
35/100 — WeakData confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −Stock is trading at 14.9 times its book value
- −Company has low interest coverage ratio.
- −Promoter holding has decreased over last quarter: -4.68%
- −The company has delivered a poor sales growth of -12.0% over past five years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Suven completed Phase-3 Masupirdine enrollment; 424 patients randomized, topline results expected by May 2027.
Monitoring agency report for Q1 FY27; no deviations in Rs 85,764.02 lakh preferential issue utilization.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Expenses + | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 |
| Operating Profit | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 |
| OPM % | -737.0% | -768.0% | -1,885.0% | -1,267.0% | -3,024.0% | -2,032.0% | -2,435.0% | -2,981.0% | -2,714.0% | -8,671.0% | -3,678.0% | -3,331.0% | -3,711.0% |
| Other Income + | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| Tax % | 0.0% | 0.0% | 0.0% | -4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit + | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| EPS in Rs | -1 | -1 | -2 | -1 | -1 | -2 | -2 | -2 | -2 | -3 | -4 | -2 | -5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 521 | 499 | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Expenses + | 361 | 398 | 414 | 427 | 300 | 128 | 93 | 134 | 139 | 140 | 172 | 291 | 375 |
| Operating Profit | 159 | 102 | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -366 |
| OPM % | 31.0% | 20.0% | 24.0% | 32.0% | -5.0% | -917.0% | -593.0% | -1,032.0% | -929.0% | -1,094.0% | -2,487.0% | -3,999.0% | -4,152.0% |
| Other Income + | 9 | 19 | 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 | 21 |
| Interest | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 12 | 18 | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 6 | 6 | 6 | 6 |
| Profit before tax | 152 | 98 | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -352 |
| Tax % | 28.0% | 26.0% | 29.0% | 37.0% | 15,038.0% | -11.0% | -7.0% | 0.0% | 0.0% | -1.0% | 0.0% | 0.0% | — |
| Net Profit + | 109 | 72 | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS in Rs | 6 | 4 | 5 | 6 | -1 | -5 | -4 | -6 | -5 | -5 | -7 | -10 | -14 |
| Dividend Payout % | 7.0% | 35.0% | 15.0% | 15.0% | -80.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 547 | 583 | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 565 |
| Borrowings + | 109 | 83 | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 17 |
| Other Liabilities + | 105 | 74 | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 16 |
| Total Liabilities | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Fixed Assets + | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 |
| CWIP | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 |
| Investments | 0 | 0 | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 |
| Other Assets + | 494 | 439 | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 367 |
| Total Assets | 773 | 751 | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 143 | 68 | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -115 | -155 | -300 |
| Cash from Investing Activity + | -110 | -39 | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from Financing Activity + | 179 | -68 | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net Cash Flow | 212 | -39 | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | -1 | -5 |
| CFO/OP | 113 | 93 | 111 | 57 | 262 | 114 | 119 | 104 | 91 | 95 | 93 | 106 |
| Free Cash Flow | 25 | 10 | 79 | 28 | -92 | -137 | -102 | -147 | -119 | -113 | -193 | -305 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 29.88% | 28.91% | 28.21% | 28.34% | 28.35% | 29.47% | 29.12% | 28.07% | 28.18% | 24.32% | 26.42% | 31.32% |
| Promoters | 69.56% | 69.56% | 70.26% | 70.26% | 70.26% | 70.26% | 70.26% | 67.36% | 67.36% | 70.15% | 70.08% | 65.47% |
| FII | 0.54% | 0.46% | 0.45% | 0.33% | 0.34% | 0.25% | 0.58% | 1.17% | 1.07% | 0.91% | 0.56% | 0.48% |
| DII | 0.01% | 1.05% | 1.05% | 1.05% | 1.05% | 0.01% | 0.03% | 3.39% | 3.39% | 4.62% | 2.93% | 2.73% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Suven Life Sciences Ltd (this stock) | 9,466 | — | 14.96 | -81.5% |
| Thyrocare Tech Ltd | 9,022 | 49.9 | 15.41 | 28.4% |
| Jupiter Life Line Hosp L | 8,706 | 45.6 | 5.65 | 13.1% |
| Aarti Pharmalabs Limited | 8,472 | 39.4 | 3.99 | 8.59% |
| Healthcare Glob. Ent. Ltd | 10,558 | 219.0 | 7.93 | 2.54% |
| Viyash Scientific Limited | 10,791 | 48.7 | 3.66 | 7.39% |
| Yatharth Hosp & Tra C S L | 10,899 | 60.2 | 6.1 | 10.4% |
Which Mutual Funds Hold Suven Life Sciences Ltd?
Frequently Asked Questions about Suven Life Sciences Ltd
Suven Life Sciences Ltd (SUVEN) closed at ₹335.0 on NSE on 25 September 2026, down 0.05 (0.01%) from the previous close.
Suven Life Sciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol SUVEN.
Suven Life Sciences Ltd has a dividend yield of 0.0%.
Suven Life Sciences Ltd's 52-week high is ₹403.0 and its 52-week low is ₹124.0.
Suven Life Sciences Ltd has a market capitalisation of ₹9,466 crore.
Suven Life Sciences Ltd has a TopFund Quality Score of 35/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Suven Life Sciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.